Milgamma Protect (Benfotiamine)

Benfotiamine, the active ingredient in Milgamma Protect, is a thiamine derivative presented as an oral dietary supplement for oral use. It is employed to support carbohydrate metabolism and to address certain complications associated with diabetes, particularly neuropathic and vascular manifestations.

GNH USA supplies Milgamma Protect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions. Clients benefit from reliable logistics, batch traceability, and responsive technical support throughout the supply chain.

Benfotiamine is used to support carbohydrate metabolism and to mitigate diabetic‑related complications. - Diabetic peripheral neuropathy: helps reduce nerve pain and improve sensory function. - Diabetic retinopathy: may protect retinal vessels and slow progression of visual impairment. - Metabolic support in diabetes: assists in normalizing glucose utilization and reducing advanced glycation end‑product formation. - Hyperglycemia‑induced oxidative stress: contributes antioxidant protection in tissues exposed to high glucose. - Peripheral vascular disease in diabetes: supports endothelial function and reduces inflammation.

Benfotiamine is generally well tolerated, but some users may experience adverse reactions.

Common Side Effects: - Nausea: occasional mild stomach upset that usually resolves without treatment. - Headache: transient headache reported in a small proportion of users. - Gastrointestinal discomfort: includes abdominal pain, bloating, or mild diarrhea. - Skin rash: mild erythema or itching that may appear on the trunk or limbs.

Serious or Rare Side Effects: - Hypersensitivity reaction: includes swelling, hives, or anaphylactic response requiring immediate medical attention. - Liver enzyme elevation: rare increases in ALT or AST indicating possible hepatic stress. - Severe cutaneous reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, demanding urgent care. - Blood disorders: rare occurrences of thrombocytopenia or leukopenia that should be monitored.

When considering benfotiamine, certain precautions should be observed to ensure safe use. - Pregnancy: safety has not been established; use only if clearly needed. - Breastfeeding: unknown effect on infants; caution advised. - Renal impairment: consider dose adjustment or monitoring in severe kidney disease. - Hepatic impairment: use with caution in patients with liver dysfunction. - Drug interactions: review concomitant medications for potential thiamine‑related effects. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and light.

Benfotiamine may interact with certain medicines; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - High‑dose thiamine supplements: combined use can lead to excess thiamine levels. - Chemotherapeutic agents affecting thiamine metabolism: may alter efficacy or toxicity.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may increase urinary thiamine loss. - Alcohol consumption: can impair thiamine absorption and counteract supplement benefits. - Anticoagulants (e.g., warfarin): theoretical risk of altered coagulation parameters. - Antibiotics such as tetracyclines: may chelate with benfotiamine reducing its absorption. - Statins: may modestly increase thiamine requirements.